Clinical research company nPhase has launched an end-to-end clinical data management platform designed to help trial sponsors ...
Neuro-focused Encoded Therapeutics has bagged a $275 million series F round to support its Dravet syndrome asset and scale up ...
Kura Oncology has spun out a biotech armed with $50 million in fresh funding to take forward a next-generation diabetes treatment. | Kura Oncology has spun out a biotech armed with $50 million in ...
Tyra Biosciences has reported initial phase 2 data on dabogratinib in bladd | Tyra Biosciences has reported initial phase 2 ...
Evommune’s G-protein coupled receptor X2 (MRGPRX2) antagonist has flunked another phase 2 trial, wiping out the biotech’s ...
A pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the ...
Novo Nordisk has given up on two more phase 3 trials of ziltivekimab, further eroding the prospects for a molecule that ...
Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...
Boston Scientific has issued another recall, this time for its spinal cord implant used to treat pain. | Boston Scientific ...
Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat ...
Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. | Luma Group announced the final close of its inaugural life sciences venture ...
ADARx Pharmaceuticals has reinvigorated its ambitions to go public as the AbbVie-backed biotech looks to fund ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results